TScan Therapeutics (TCRX) FCF Margin (2020 - 2026)
TScan Therapeutics' (TCRX) quarterly FCF Margin came in at 2666.79% in Q2 2026, down 154371.0% year-over-year from N/an in Q2 2025, and down 7.55% quarter-over-quarter from 2479.53% in Q1 2026.
Powered by 
Analysis
TScan Therapeutics (TCRX) FCF Margin (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported FCF Margin for 7 consecutive years, with 2666.79% the latest figure, recorded in Q2 2026.
- On a quarterly basis, FCF Margin fell 154371.0% year-over-year to 2666.79% in Q2 2026; TTM through Jun 2026 was 1665.57%, a 21996.0% increase from a year earlier, with the FY2025 full-year figure at 1353.28%, up 271799.0% from the prior year.
- FCF Margin was 2666.79% for Q2 2026 at TScan Therapeutics, down from 2479.53% in the prior quarter.
- Over five years, FCF Margin peaked at 169.75% in Q3 2023 and troughed at 5295.41% in Q1 2024.
- A 5-year average of 1747.16% and a median of 1188.21% in 2025 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin tumbled 493637 bps in 2024 and jumped 393046 bps in 2025, its largest moves.
- Over 5 years, FCF Margin stood at 561.78% in 2022, then soared by 40 bps to 336.08% in 2023, then slumped by 1166 bps to 4255.64% in 2024, then surged by 71 bps to 1253.33% in 2025, then tumbled by 113 bps to 2666.79% in 2026.
- The last three FCF Margin figures came in at 2666.79% (Q2 2026), 2479.53% (Q1 2026), and 1253.33% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 59.74% |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | -826.50% |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | -66.71% |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | -3.46% |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | -497.31% |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | -13,981.63% |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | -33.11% |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 48.98% |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 18.67% |
| 10 | TScan Therapeutics | 42.91 Mn | 42.91 Mn | - | -2,666.79% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,666.79% |
| Mar 31, 2026 | -2,479.53% |
| Dec 31, 2025 | -1,253.33% |
| Sep 30, 2025 | -1,349.62% |
| Jun 30, 2025 | -1,123.08% |
| Mar 31, 2025 | -1,801.84% |
| Dec 31, 2024 | -4,255.64% |
| Sep 30, 2024 | -2,791.99% |
| Jun 30, 2024 | -5,053.54% |
| Mar 31, 2024 | -5,295.41% |
| Dec 31, 2023 | -336.08% |
| Sep 30, 2023 | 169.75% |
| Jun 30, 2023 | -712.90% |
| Mar 31, 2023 | -359.03% |
| Dec 31, 2022 | -561.78% |
| Sep 30, 2022 | -518.17% |
| Jun 30, 2022 | -376.23% |
| Mar 31, 2022 | -683.71% |
| Dec 31, 2021 | -581.32% |
| Sep 30, 2021 | -600.87% |